Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.
Follow REGN
Regeneron Pharmaceuticals, Inc. (REGN) Gross margin
Regeneron Pharmaceuticals, Inc.'s gross margin over the twelve months to 30 June 2026 was 84.9%, down 0.5 percentage points from fiscal 2025 (85.4%). Over the past ten years it has ranged from 84.8% (fiscal 2021) to 93.8% (fiscal 2016); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 85.4% | (0.78) |
| FY2024 | 86.1% | (0.03) |
| FY2023 | 86.2% | (1.02) |
| FY2022 | 87.2% | 2.35 |
| FY2021 | 84.8% | (1.99) |
| FY2020 | 86.8% | (1.51) |
| FY2019 | 88.3% | (3.56) |
| FY2018 | 91.9% | (1.35) |
| FY2017 | 93.2% | (0.59) |
| FY2016 | 93.8% | 3.40 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 86.6% | 5.13 |
| Mar 2026 | 81.4% | (3.52) |
| Dec 2025 | 85.0% | (1.16) |
| Sep 2025 | 86.1% | 0.53 |
| 42 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 100.0% |
| ARGX argenex SE compare | 90.2% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 88.9% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 86.0% |
| REGN Regeneron Pharmaceuticals, Inc. | 84.9% |
| ROIV Roivant Sciences Ltd. compare | 81.2% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 79.7% |
| RVMD Revolution Medicines, Inc. compare | 35.1% |
| MRNA Moderna, Inc. compare | 23.4% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.5% |
| Market median | 46.2% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement